drugset / Trial / NCT00380211

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

NCT00380211

Phase 3 Completed 660 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator. The results will be compared to a standard immune response criteria, for both young and elderly populations.

Timeline

Start
2006-09
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject FluLaval™ TR Vaccine
Subject Influenza Virus Vaccine Vaccine

Indications